Sanofi (SNY) says the largest U.S. real-world study of Beyfortus met both of its co-primary endpoints, demonstrating the drug provides protection for babies against RSV disease. The first co-primary endpoint showed babies administered Beyfortus were 87% less likely to develop RSV disease compared to babies who did not receive Beyfortus. The second co-primary endpoint showed that if a baby who received Beyfortus later tested positive for RSV lung infection there were fewer overall medical visits during the illness, Sanofi announced. The study included more than 30,000 healthy, full-term babies.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNY:
- Sanofi’s SAR446597 Gains Fast Track Status and Vicebio Acquisition Announced
- Sanofi’s Chlamydia Vaccine Study: A Promising Step Forward
- Sanofi’s Innovative Approach in Type 1 Diabetes Treatment: A Clinical Study Update
- Sanofi’s New Study on Lunsekimig for Chronic Rhinosinusitis: A Potential Game Changer?
- Regeneron and Sanofi’s Dupilumab Study: A Potential Breakthrough in Eosinophilic Gastritis Treatment